ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2691

Increased Plasma Angiopoietin-2 in Systemic Sclerosis: Potential for Use As a Biomarker of Vasculopathy and Fibrosis

Victoria Flower1,2, Shaney Barratt3,4, Darren Hart5, Amanda MacKenzie2, Jacqueline Shipley5, Stephen Ward2 and John Pauling1,2, 1Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom, 2Centre for Therapeutic Innovations & Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 3Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, 4North Bristol NHS Trust, Bristol, United Kingdom, 5Clinical Measurement Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: angiopoietin, fibrosis, nailfold capillaroscopy, systemic sclerosis and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Angiogenic pathways are likely to contribute to pathogenesis of both vasculopathy and fibrosis in Systemic sclerosis (SSc). The angiogenic actions of Angiopoietins (pro-angiogenic Ang1 and divergent Ang2) through competitive Tie2 binding could be attractive biomarkers in SSc. We report the association between Ang1, Ang 2 and Tie2 with objective assessments of peripheral vasculopathy and cutaneous fibrosis in SSc.

Methods:

Fifty-one SSc patients (2013 ACR/EULAR criteria) and fifteen healthy controls (HC) underwent functional assessment of post-occlusive digital vascular responses using Laser Speckle Contrast Imaging (LSCI), morphological capillary assessment using nailfold capillaroscopy (NC) and High Frequency Ultrasound (HFUS) assessment of cutaneous fibrosis and digital vasculopathy. Modified Rodnan Skin Score (mRSS) and Raynaud’s Condition Score were assessed in SSc. Plasma Ang 1, Ang 2 and Tie2 levels were measured using ELISA.

Results:

Ang2 was significantly increased in SSc compared to HC (Figure 1). There was no significant difference in Ang1 or soluble Tie2, however Ang1/2 ratio was significantly reduced in SSc compared to HC (median 4.4 versus 6.2, p=0.018). In SSc, Ang2 demonstrated a weak negative correlation with the post-occlusive reperfusion gradient on LSCI and a weak positive correlation with inter-capillary distance (Table 1), suggesting an association between impaired functional and structural microangiopathy and increased Ang2. Ang2 progressively increased with progressive NC qualitative classification (early, active and late, Figure 2). Interestingly, Ang2 also correlated weakly with Echogenicity and Shear wave Elastography on HFUS, suggesting an association with skin fibrosis. Ang1 had a weak positive correlation with Echogenicity only suggesting that as the oedematous phase of SSc skin disease resolves, Ang1 increases. The lack of significant correlation between Ang1 and Elastography suggests there is no clear association with fibrosis (Table 1).

Conclusion:

Our findings suggest that Ang2 may reflect anti-angiogenic and pro-fibrotic mechanisms in SSc. Further study is warranted to explore the relative expression of Angiopoietins in well phenotyped SSc patients and evaluate their role as novel biomarkers.


 


 


 


Disclosure: V. Flower, None; S. Barratt, None; D. Hart, None; A. MacKenzie, None; J. Shipley, None; S. Ward, None; J. Pauling, None.

To cite this abstract in AMA style:

Flower V, Barratt S, Hart D, MacKenzie A, Shipley J, Ward S, Pauling J. Increased Plasma Angiopoietin-2 in Systemic Sclerosis: Potential for Use As a Biomarker of Vasculopathy and Fibrosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/increased-plasma-angiopoietin-2-in-systemic-sclerosis-potential-for-use-as-a-biomarker-of-vasculopathy-and-fibrosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-plasma-angiopoietin-2-in-systemic-sclerosis-potential-for-use-as-a-biomarker-of-vasculopathy-and-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology